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Objective
Medium-grade proteinuria (100–500 mg/g creatinine) is common among people living with HIV/
AIDS (PLWHA) but is often undetected or ignored. This prospective, observational cohort study
examined medium-grade proteinuria as a risk factor for markers of chronic kidney disease (CKD).
Methods
Quantitative urine samples were collected from 241 PLWHA without known renal disease at
baseline between January 2009 and February 2011 and at follow-up 240 weeks later. Multivariate
analysis was performed to assess medium-grade proteinuria as a risk factor for incident markers of
CKD (estimated glomerular filtration rate < 60 mL/min/1.73 m2, albuminuria, phosphaturia).
Results
Incident markers of CKD were identified in 33 patients (14%), of whom 24 (74%) had medium-
grade proteinuria at baseline. Of these, 22 even had proteinuria of < 200 mg/g creatinine.
Multivariate analysis showed an adjusted relative risk (aRR) of 2.4 for patients with baseline
medium-grade proteinuria to develop signs of CKD. Age was identified as an additional
independent predictor. By testing for interaction, tenofovir disoproxil fumarate (TDF)-independent
proteinuria was strongly associated with incident CKD markers (aRR = 12.1).
Conclusion
Medium-grade proteinuria of 100–500 mg/g creatinine is both frequent in PLWHA and a
significant risk factor for developing markers of CKD, especially in the absence of TDF. Relevant
risk seems to be associated with proteinuria levels as low as 100–200 mg/g creatinine. Current
guidelines recommend specific action for proteinuria exceeding 135–200 mg/g but still will miss a
relevant number of PLWHA potentially at risk for CKD. An even lower cut-off to trigger
nephrological work-up and potentially renoprotective interventions appears to be indicated.
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Introduction
Since the introduction of antiretroviral (ARV) therapy,
HIV-associated mortality has decreased and life
expectancy has improved dramatically [1]. Ageing of
people living with HIV/AIDS (PLWHA) leads to an
increase in age-related non-communicable diseases
(NCDs), such as non-AIDS-related malignancies, cardio-
vascular disease, diabetes mellitus, and chronic kidney
disease (CKD) [2,3]. Among those comorbidities, CKD is
very common [4-8]. In the HIV-uninfected population
CKD is mainly associated with age, diabetes mellitus,
arterial hypertension, obesity, and also coronary heart
disease [9]. PLWHA are additionally exposed to poten-
tial both viral and immunologic nephrotoxicity as well
as effects caused by ARV treatment, which nowadays is
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usually started early after diagnosis [10]. Especially the
nucleotide reverse transcriptase inhibitor tenofovir diso-
proxil fumarate (TDF) is associated with kidney damage
due to proximal tubular dysfunction [4-8,11-13].
People living with HIV/AIDS not only are at higher
risk for CKD, but studies also show that its progress is
more rapid compared with uninfected individuals [14].
As CKD is a significant cause of morbidity and mortality
[15,16], early identification of patients at risk should be
a key premise of physicians treating PLWHA. Signs of
CKD include a decreased glomerular filtration rate (GFR)
below 60 mL/min/1.73 m2, albuminuria over 30 mg/g
creatinine, urine sediment or electrolyte abnormalities,
as well as abnormalities detected by histology or imag-
ing [17].
Urinary loss of large proteins such as albumin, trans-
ferrin or immunoglobulins suggests impairment of the
glomerular filter which is often caused by diabetes melli-
tus or arterial hypertension [18]. On the other hand,
infections, nephrotoxins, or some hereditary conditions
lead to damage of the tubular system. As a consequence,
pathological amounts of rather smaller proteins, e.g.,
alpha-1 microglobulin, become detectable [19]. In most
instances, these two forms of proteinuria cannot be com-
pletely distinguished. Diagnostic modality of choice is
quantitative urinalysis. The updated European AIDS Clini-
cal Society (EACS) guidelines suggest checking GFR every
3–12 months and performing a dipstick or quantitative
urinalysis annually. Albuminuria > 30 mg/g creatinine as
well as proteinuria > 135–150 mg/g is considered to be
pathological and should result in further diagnostic and
therapeutic actions [20].
Several studies have shown that medium-grade pro-
teinuria is frequent in PLWHA [4,6], with a prevalence
ranging up to > 50%, depending on the cut-off [21]. A
previous study performed at our HIV outpatient clinic
between 2009 and 2011 detected medium-grade pro-
teinuria with a urinary protein/creatinine ratio (uPCR)
from 100 to 500 mg/g in 56% of patients. Of those,
66% had proteinuria without albuminuria, suggesting
low-molecular-weight proteinuria of tubular origin.
There was a significant association with exposure to
TDF, older age, lower CD4-positive T-lymphocyte-
(CD4-) nadir and hepatitis C infection [22]. While pro-
teinuria in general is a known risk factor for CKD [4-
6,23], the prognostic relevance of merely medium- or
even low-grade proteinuria in PLWHA has not been
defined.
The objective of this follow-up study, therefore, was to
examine whether medium-grade proteinuria of 100–
500 mg/g creatinine is a risk factor for incident renal
dysfunction in PLWHA.
Methods
Setting and patient population
This prospective observational cohort study was con-
ducted at the HIV outpatient clinic of the University
Hospital of Ludwig-Maximilians-University in Munich,
Germany. The university ethics committee approved the
protocol (project no. 153-14). Written informed consent
was obtained from every patient entering the study. The
data were collected at two time points: first during the
baseline visit between January 2009 and February 2011,
and then during a follow-up visit on average 240 weeks
later. Inclusion criteria were age > 18 years, written con-
sent, a confirmed diagnosis of HIV infection, as well as a
visit during the period January 2009 to February 2011.
On both visits, blood samples and a quantitative urine
sample were collected as part of routine patient care.
Exclusion criteria were any history of renal disease before
the first visit, a confirmed diagnosis of CKD at the base-
line visit, fever or a urinary tract infection at the time of
examination, and any other known causes of proteinuria,
including amyloidosis, pregnancy, or sickle cell disease.
Blood and urine samples were analysed in the context
of routine laboratory testing during the quarterly routine
control visits. A uPCR of 100–500 mg/g at the baseline
visit was defined as medium-grade proteinuria. In addi-
tion, urinary albumin/creatinine ratio (uACR), fasting uri-
nary phosphate/creatinine ratio (uPhoCR), and urinary
a1-microglobulin/creatine ratio were measured. Estimated
GFR (eGFR) was calculated using the CKD-Epi creatinine
equation [17]. Laboratory testing also included a com-
plete blood count with differential, serum creatinine, and
serum electrolytes. For all patients, current CD4 T-cell
count and plasma viral load were measured.
Demographic and additional medical data, such as
comorbidities, blood pressure, height, weight, and current
medication, including ARV therapy, were collected from the
patients’ files. Hypertension was defined as current use of
antihypertensive drugs or systolic or diastolic blood pres-
sure > 140 or > 90 mmHg, respectively. Diabetes mellitus
was defined as current use of oral antidiabetic medication or
insulin, HbA1c > 6.5% or any blood glucose measurement
> 200 mg/dL. Hepatitis B and C infection were diagnosed
by serological testing (anti-HBc antibodies, HBs antigen,
anti-HCV antibodies, and HCV-PCR).
The main outcome was detection of incident early
markers of renal dysfunction at the 240-week follow-up,
defined by at least one of the following criteria: eGFR
< 60 mL/min/1.73 m2, uACR > 30 mg/g, or uPhoCR
> 1000 mg/g, markers used for definition of CKD if found
to be confirmed [17].
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Statistical methods
The study is a retrospectively documented, but prospec-
tively analysed cohort study. Categorical variables are
shown as count and percentage and were analysed using
Pearson’s v2-test or Fisher’s exact test; continuous vari-
ables are shown as median and interquartile range (IQR)
and were analysed using Wilcoxon–Mann–Whitney test
or Student’s t-test for unpaired data. To analyse the asso-
ciation between medium-grade proteinuria and different
baseline and outcome variables measured as relative risk
(RR) estimates, univariate analysis was performed:
patients with uPCR < 100 mg/g at baseline were com-
pared to those with uPCR of 100–500 mg/g.
A multivariate analysis for the main outcome variable
incident CKD markers (eGFR < 60 mL/min/1.73 m2, uACR
> 30 mg/g, or uPhoCR > 1000 mg/g) was performed using
a modified Poisson regression model with a robust error
variance [24,25]. This allows robust estimates of adjusted
relative risk (aRR) as a measure of association. Variables
with statistically significant association in univariate anal-
ysis or known risk factors for CKD in the current literature
were included in the primary (full) multivariate model.
Collinearity was assessed and, in the case of competing
variables, the monodimensional instead of the compound
variables or the more strongly associated variable were
entered into the model (i.e. serum creatinine and age but
not eGFR; age but not duration of HIV infection). Ln-linear-
ity of continuous variables (age, body mass index, current
CD4 cell count) was ensured. Manual backward elimination
was used based on the influence on the aRR for medium-
grade proteinuria to construct the final model. The final
model includes significant independent predictors and
potential confounders. Constructing a hierarchically well-
formulated model also allowed us to assess the interaction
between variables [26]. To rule out subjective influence on
variable selection, additional models were derived using
automated algorithms (SAS 9.4, proc hpgenselect, forward
selection, stepwise regression, backward elimination).
Analyses were performed using SPSS 24 (IBM Inc.,
Armonk, NY, USA) and SAS 9.4 (SAS Institute Inc., Cary,
NC, USA). A P-value < 0.05 was considered statistically
significant, except for the analysis of interaction for
which a cut-off of 0.1 was used.
Results
The initial study had enrolled 393 patients. For this fol-
low-up analysis 84 (21%) were excluded because they
already had shown signs of CKD at baseline. For 68
(22%) of the remaining 309 patients no 240-week follow-
up data were available. Reasons were death, missing
written consent, change of HIV care provider, or acute
urinary tract infection at the time of follow-up (Fig. 1).
Characteristics of the cohort that qualified for the final
analysis are shown in Tables 1 and 2: of 241 patients,
186 (77%) were male and 194 (80%) were of Caucasian
descent. At baseline, median time since HIV infection was
9.3 years, median age was 44.8 years. Main HIV risk fac-
tors were homosexual (n = 120, 50%) and heterosexual
(n = 60, 25%) contacts. At baseline and follow-up dia-
betes mellitus was diagnosed in 12 (5%) and 15 patients
(6%), and hypertension in 49 (20%) and 68 patients
(28%), respectively. Twenty-eight (12%) and 31 (13%)
were positive for anti-HCV antibodies, and HCV-RNA was
detectable in 11 (4%) and 10 (4%), respectively. Median
eGFR was 105 mL/min/1.73 m2 at baseline and decreased
to a median of 88 mL/min/1.73 m2 over the course of the
study. By definition, none of the patients had significant
uACR > 30 mg/g at baseline.
At baseline, 126 patients (52%) had no significant pro-
teinuria (uPCR < 100 mg/g), while 115 (48%) had med-
ium-grade proteinuria (uPCR 100–500 mg/g). This group
was significantly older [50.5 years compared with
48.0 years at follow-up (P = 0.001)] and duration of HIV
infection was longer (16.0 vs. 13.0 years, P = 0.012). The
CD4 cell count nadir was significantly higher in the group
with a uPCR < 100 mg/g, both at baseline (232 vs. 173
cells/µL, P = 0.009) and at follow-up (202.5 vs. 170 cells/
µL, P = 0.015). In addition, while the current CD4 count
was not significantly different between groups at baseline,
at follow-up the group with uPCR of 100–500 mg/g had a
significantly lower current CD4 count (616 vs. 643.5 cells/
µL, P = 0.028). With respect to ARV therapy, patients with
uPCR of 100–500 mg/g used TDF significantly more often
at baseline (P = 0.012). At follow-up, TDF had been
stopped significantly more often in the group with uPCR
of 100–500 mg/g: 15 (22% of patients with TDF at base-
line, 13% overall) compared with seven (9% of patients
with TDF at baseline, 6% overall) (P = 0.044). There were
no significant differences between the groups relating to
other comorbidities (Tables 1 and 2).
At follow-up eGFR had dropped below 60 mL/min/
1.73 m2 in 11 patients (5%), uACR had increased to
> 30 mg/g in 20 (8%), and uPhoCR to > 1000 mg/g in
seven (3%). Combining these criteria, signs of incident
chronic kidney disease were detected in 33 patients overall
(14%) at follow-up (Tables 1 and 2; Fig. 2). In 29 patients a
single criterion was pathological, in three patients new-on-
set albuminuria was found in addition to either phospha-
turia (2) 60 mL/min/1.73 m2 (1), and in one patient all
three criteria exceeded the predefined thresholds. Within
the group of patients with medium-grade proteinuria at
baseline 24 (21%) developed markers for CKD: eGFR had
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dropped to < 60 mL/min/1.73 m2 in nine, uACR had
increased to > 30 mg/g in 14, and uPhoCR to > 1000 mg/g
in three patients. Among the 33 patients meeting the end-
point 4 (12%) had a diagnosis of diabetes mellitus and 12
(36%) of arterial hypertension at baseline. None of them
had HCV-RNA detectable at baseline.
Multivariate analysis (Fig. 3) confirmed the univariate
finding of a baseline uPCR of 100–500 mg/g as an inde-
pendent risk factor to develop markers of CKD at follow-
up, with an aRR of 2.4 (P = 0.024). In addition, age was
an independent predictor (aRR 1.03/year, P = 0.017).
While arterial hypertension and CD4 nadir were
associated with incident signs of CKD in univariate anal-
ysis, this was no longer significant in multivariate analy-
sis. Exposure to TDF at baseline was not a significant risk
factor in the overall study population (Fig. 3). However,
in addition to age, use of TDF was identified as a con-
founder for the association between baseline medium-
grade proteinuria and incident CKD and therefore
adjusted for in the multivariate model. Finally, the multi-
variate regression model was assessed for interaction
(Table 3). There was a significant interaction between
medium-grade proteinuria and exposure to TDF at base-
line. Thus, the aRR for incident markers of CKD
Fig. 1 Study design and patient disposition. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; uACR: urinary albumin/cre-
atinine ratio; uPCR, urinary protein/creatinine ratio.
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associated with medium-grade proteinuria was 12.1 for
patients without baseline TDF exposure (P = 0.023),
whereas the association was not statistically significant
for patients exposed to TDF at baseline (aRR = 1.64,
P = 0.17). Also, the effect of age was dependent on both
serum creatinine levels and CD4 nadir. The robustness of










N = 241 N = 126 (52%) N = 115 (48%)
N (%) N (%) N (%)
Male gender 186 (77%) 99 (79%) 87 (76%) 0.646
Race
Caucasian 194 (81%) 95 (75%) 99 (86%) 0.036
African American 29 (12%) 19 (15%) 10 (9%) 0.128
Other 18 (8%) 12 (10%) 6 (5%)
Risk of infection
Heterosexual 60 (25%) 31 (25%) 29 (25%) 0.912
Homosexual 120 (50%) 61 (48%) 59 (51%) 0.965
Intravenous drug use 11 (5%) 4 (3%) 7 (6%) 0.279
Blood products 2 (1%) 1 (1%) 1 (1 %) 1.000
Origin from endemic country 42 (17%) 25 (20%) 17 (15%) 0.301
Other/unknown 6 (2%) 4 (3%) 2 (2%)
Baseline visit
Diabetes mellitus 12 (5%) 5 (4%) 7 (6%) 0.450
Arterial hypertension 49 (20%) 23 (18%) 26 (23%) 0.401
Anti-HCV antibodies positive 28 (12%) 11 (9%) 17 (15%) 0.143
HCV-RNA-positive 11 (5%) 3 (2%) 8 (6%) 0.089
Current TDF exposure 139 (58%) 63 (50%) 76 (66%) 0.012
Serum creatinine > 0.8 mg/dL 103 (43%) 62 (49%) 41 (36%) 0.034
eGFR < 60 mL/min/1.73 m2 0 (0%) 0 (0%) 0 (0%)
uACR > 30 mg/g 0 (0%) 0 (0%) 0 (0%)
Tubular proteinuria 115 (48%) 0 (0%) 115 (100%)
HIV-RNA < 50 copies/mL 199 (8 %) 100 (80%) 99 (86%) 0.169
Follow-up visit
Diabetes mellitus 15 (6%) 7 (6%) 8 (7%) 0.653
Arterial hypertension 68 (28%) 31 (25%) 37 (32%) 0.192
Anti-HCV antibodies positive 31 (13%) 11 (9%) 20 (13%) 0.045
HCV-RNA-positive 10 (4%) 1 (0.8%) 9 (6%) 0.008
HIV-RNA < 50 copies/mL 230 (95%) 120 (95%) 110 (96%) 0.878
Progress of HIV infection 33 (14%) 18 (14%) 15 (13%) 0.779
Current TDF exposure 147 (70%) 78 (62%) 69 (60%) 0.762
TDF started 30 (12%) 22 (18%) 8 (7%) 0.014
TDF stopped 22 (9%) 7 (6%) 15 (13%) 0.044
ATV started 6 (3%) 5 (4%) 1 (1%) 0.106
ATV stopped 16 (7%) 7 (6%) 9 (8%) 0.106
COBI started 11 (5%) 3 (2%) 8 (7%) 0.123
DTG started 15 (6%) 6 (5%) 9 (8%) 0.426
ACE inhibitor started 19 (8%) 7 (6%) 12 (10%) 0.160
RAS inhibitor started 22 (9%) 9 (7%) 13 (11%) 0.263
Serum creatinine > 0.8 mg/dL 165 (68%) 87 (69%) 78 (68%) 0.838
eGFR < 60 mL/min/1.73 m2 11 (5%) 2 (2%) 9 (8%) 0.020
Cystatin C > 1.1 mg/dL 44 (18%) 16 (13%) 28 (24%) 0.019
Quantitative urinalysis
uPCR > 100–500 mg/g 92 (38%) 31 (25%) 61 (53%) < 0.001
uACR > 30 mg/g 21 (9%) 6 (5%) 15 (13%) 0.037
Tubular proteinuria 71 (30%) 25 (20%) 46 (40%) 0.001
a1-microglobulin/creatinine ≥ 14 mg/g 77 (32%) 20 (16%) 57 (50%) < 0.001
IgG/creatinine > 12 mg/g 24 (10%) 11 (9%) 13 (11%) 0.505
Incident markers of CKD 33 (14%) 9 (7%) 24 (21%) 0.002
ACE, angiotensin-converting enzyme; ATV, atazanavir; CKD, chronic kidney disease; COBI, cobicistat; DTG, dolutegravir; eGFR, estimated glomerular fil-
tration rate; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IgG, immunoglobulin G; RAS, renin–angiotensin system (RAS inhibitor defined
as ACE inhibitor and/or angiotensin-receptor blocker); RNA, ribonucleic acid; TDF, tenofovir disoproxil fumarate; uACR, urinary albumin/creatinine ratio;
uPCR, urinary protein/creatinine ratio. Statistically significant associations shown in bold.
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our findings was confirmed by additional models derived
using automated variable selection algorithms (data not
shown).
Discussion
In our cohort of 241 PLWHA we demonstrate that despite
the absence of known kidney disease at baseline more
than one in five patients with merely medium-grade pro-
teinuria developed markers of CKD after a median fol-
low-up of 240 weeks. Thus, the presence of medium-
grade proteinuria (uPCR 100–500 mg/g) was associated
with a greater than two-fold risk for developing signs of
CKD (aRR = 2.4, P = 0.024). A surprisingly high risk for
incident CKD markers was identified for patients with
medium-grade proteinuria and no concurrent use of TDF
at baseline (aRR = 12.1, P = 0.023).
In accordance with our previous investigation [22]
others have shown that proteinuria is highly prevalent in
predominantly Caucasian PLWHA in Germany, with a
uPCR > 70 mg/g in 55% of patients. Even for this low
cut-off the authors were able to identify the classic risk
factors of older age, diabetes mellitus, and exposure to
TDF [21]. In addition to the high prevalence of protein-
uria the increased risk for CKD among PLWHA has been
well known for decades, and clear definitions have been
used already in the pre-TDF era [27]. Already in 2004
Gupta described an association between proteinuria and
the incidence of CKD in PLWHA [23]. However, in that
study, proteinuria was evaluated by dipstick only. Their
analysis therefore had a lower sensitivity compared with
our investigation and also missed tubular proteins. Their
definition of CKD also resulted in a much lower incidence
of only 2%, as they and others [28] used eGFR only,
while current Kidney Disease: Improving Global Out-
comes (KDIGO) guidelines call for evaluation by eGFR
and quantitative urinalysis [17].
Our results now not only confirm the high prevalence
of proteinuria found in PLWHA [4,6,21,23] and the high
risk of renal dysfunction in this population [4-
7,12,14,23], but also underline the prognostic relevance
of even medium-grade proteinuria of < 500 mg/g crea-
tinine as an early indicator of increased risk for markers
of CKD. The cut-off of 500 mg/g initially chosen in 2009
resulted from our clinical experience that in the absence
of pre-existing renal disease specific nephrological work-
up or renoprotective measures were essentially never
deemed necessary for values observed in this range,
despite them being reported as abnormal. In our prospec-
tive cohort, 106 (92%) out of the 115 patients with








N = 241 N = 126 (52%) N = 115 (48%)
Median (IQR) Median (IQR) Median (IQR)
Baseline visit
Age (years) 44.8 (38.8–52.2) 43.6 (36.9–48.9) 45.8 (40.4–56.2) 0.001
BMI (kg/m2) 23.9 (22.1–26.8) 24.6 (22.1–27.7) 23.5 (22.1–25.6) 0.022
Serum creatinine (mg/dL) 0.8 (0.7–0.9) 0.8 (0.7–0.9) 0.8 (0.7–0.9) 0.16
eGFR [CKD-Epi (mL/min/1.73 m2)] 105.02 (96.29–115.37) 108.10 (97.23–117.39) 104.91 (92.51–114.91) 0.049
uPCR (mg/g) 96 (69.5–129.0) 70.0 (53.0–84.3) 130.0 (112.0–161.0) < 0.001
uACR (mg/g) 10.0 (10.0–10.0) 10.0 (10.0–10.0) 10.0 (10.0–15.0) < 0.001
Time since HIV diagnosis (years) 9.3 (3.5–15.9) 8.0 (3.3–14.5) 11.3 (4.6–17.5) 0.010
CD4 nadir (cells/lL) 196.0 (81.0–321.0) 232.0 (111.5–362.5) 173.0 (59.0–272.0) 0.009
Current CD4 cell count (cells/lL) 538.0 (337.5–701.0) 558.0 (365.0–697.0) 506.0 (309.0–709.0) 0.132
Follow-up visit
Age (years) 49.6 (43.3–57.1) 48.0 (41.5–53.6) 50.5 (44.8–60.7) 0.001
BMI (kg/m2) 21.7 (19.6–24.6) 22.5 (19.5–24.7) 21.2 (19.8–24.3) 0.144
Tim’s e since HIV diagnosis (years) 14.0 (8.0–20.5) 13.0 (8.0–19.0) 16.0 (9.0–22.0) 0.012
CD4 nadir (cells/lL) 190.0 (78.5–305.5) 202.5 (102.0–324.5) 170.0 (59.0–250.0) 0.015
Current CD4 count (cells/lL) 626.0 (492.0–802.0) 643.5 (517.5–843.8) 616.0 (408.0–746.0) 0.028
Serum creatinine (mg/dL) 1.0 (0.8–1.1) 1.0 (0.8–1.1) 1.0 (0.8–1.1) 0.528
eGFR [CKD-Epi (mL/min/1.73 m2)] 88.35 (76.53–101.83) 91.06 (78.66–104.34) 83.56 (73.95–99.11) 0.006
Cystatin C (mg/dL) 0.92 (0.81–1.04) 0.88 (0.79–0.99) 0.96 (0.87–1.11) 0.002
uPCR (mg/g) 83.5 (62.6–114.5) 70.0 (55.9–93.6) 102.0 (72.6–134.0) 0.000
uACR (mg/g) 10.0 (9.1–11.2) 10.0 (10.0–18.5) 10.0 (10.0–15.1) 0.008
a1-microglobulin/creatinine (mg/g) 7.0 (7.0–17.7) 7.0 (7.0–9.0) 13.4 (7.0–29.5) < 0.001
IgG/creatinine (mg/g) 5.8 (3.9–7.0) 4.9 (3.5–6.0) 6.0 (4.0–7.9) 0.003
BMI, body mass index; CD4, CD4-positive T-helper lymphocytes; eGFR, estimated glomerular filtration rate; HIV, human immunodeficiency virus; IgG,
immunoglobulin G; uACR, urinary albumin/creatinine ratio; uPCR, urinary protein/creatinine ratio. Statistically significant associations shown in bold.
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medium-grade proteinuria at baseline even had uPCR
levels of only 100–200 mg/g. At follow-up 22 of these
(21%) showed CKD markers, representing the vast major-
ity (22/24, 92%) of persons in the medium-grade protein-
uria group to do so and at a proportion basically
identical to the 2/9 (22%) of patients with baseline uPCR
of 200–500 mg/g. This suggests that even a level of pro-
teinuria close to the upper limit of normal, a finding
which is frequently seen in PLWHA, is a relevant predic-
tor of renal dysfunction.
Interestingly, proteinuria independent of current TDF
use at baseline was associated with a much higher risk
for developing signs of CKD. TDF has long been recog-
nized for its potential nephrotoxicity, which is reversible
if identified early [13,29]. The judicious use of this ARV
drug is reflected in our data, which show that in patients
with medium-grade proteinuria TDF had been stopped
significantly more often. Suspicion of TDF use as a
potential cause of proteinuria or at least contributing to
potential nephrotoxicity thus apparently led to optimiza-
tion of the ARV regimen as a modifiable risk factor. Sim-
ilarly, a numerically larger proportion of patients with
medium-grade proteinuria at baseline were started on
angiotensin-converting-enzyme inhibitors or angiotensin-
receptor blockers, even though this did not reach statisti-
cal significance. Both observations demonstrate the value
and effect of quantitative urinalysis in PLWHA; also, this
differential treatment most likely ameliorated the overall
risk associated with medium-grade proteinuria at base-
line.
Experts on HIV-associated renal disease recently con-
vened by KDIGO recommend monitoring both eGFR and
urine markers including those specific for tubular dys-
function [5]. They suggest at least yearly assessments and
set the uPCR cut-off for the definition of ‘high risk’ at
200 mg/g. In their 2019 update, the European AIDS Clin-
ical Society (EACS) guidelines now recommend further
diagnostic and therapeutic actions including considera-
tion of replacing TDF for patients with albuminuria
≥ 3 mg/mmol or proteinuria ≥ 15 mg/mmol, equivalent
to 135–150 mg/g creatinine [20]. This constitutes a sig-
nificant change from the previous recommendation of
‘regular follow-up’ for uPCR levels up to 442 mg/g [30].
Fig. 2 Cohort overview by tenofovir disoproxil fumarate (TDF) status
and level of proteinuria at baseline. Two hundred and forty-one
people living with HIV/AIDS (PLWHA) without chronic kidney disease
(CKD) at baseline were followed for a median of 240 weeks. Black
rectangles on the left indicate PLWHA taking TDF at baseline. Bars
show urinary protein/creatinine ratio (uPCR, mg/g) at baseline; levels
up to 100 mg/g (dashed line) were considered normal. Black bars
indicate PLWHA with incident markers of CKD at follow-up.
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In our study, 14% of all patients developed signs of CKD;
considering only the patients with medium-grade protein-
uria at baseline, the incidence was even higher, at 21%.
All 33 PLWHA with CKD markers at follow-up had base-
line uPCR levels well below 442 mg/g. In only two of
them did uPCR exceed the level of 200 mg/g; the cut-off
suggested by KDIGO experts therefore would have
resulted in a sensitivity of merely 6%. Setting the cut-off
for potentially pathological proteinuria to the uPCR level
of 100 mg/g identified 24/33 (73%) PLWHA who eventu-
ally would show markers of CKD, resulting in a negative
predictive value of 92% in our study population, while
Fig. 3 Comparison of potential risk factors at baseline for developing incident markers of chronic kidney disease (CKD) after 240 weeks of fol-
low-up by univariate and multivariate analysis. Risk ratio estimates (RR) are shown as black squares for univariate analysis, and adjusted RR
estimates (aRR) are shown as grey diamonds for multivariate analysis. Error bars indicate 95% confidence intervals (CI). Numbers and graphs
do not take interaction into account. ATV, atazanavir; CD4, CD4-positive T-helper lymphocytes; HCV, hepatitis C virus; TDF, tenofovir disoproxil
fumarate. Statistically significant associations shown in bold.
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such proteinuria levels were also found in 102/208
PLWHA with no apparent renal abnormalities at follow-
up, resulting in a specificity of 51% and a positive pre-
dictive value of 19% in the study population. Given that
the recommended measures for suspected renal dysfunc-
tion in PLWHA [5,20] – including evaluation and poten-
tial modification of medication and risk factors, renal
ultrasound, and potentially referral to a nephrologist –
are well defined, straightforward and primarily non-inva-
sive, this cut-off level seems to result in a very reason-
able balance of sensitivity and specificity. With CKD
known to be associated with significantly increased mor-
bidity and mortality in PLWHA [3,16], using this even
lower than currently suggested cut-off therefore appears
to be warranted.
This study has several limitations but also a number of
strengths that merit discussion. It was performed as a
monocentric study, so selection bias cannot be ruled out
and the results may not be applicable to PLWHA in other
settings, specifically those with different age, gender or
ethnic distribution. However, a comparison with the Ger-
man national epidemiological data of the Robert Koch
Institute indicates that our study population adequately
represents PLWHA in Germany [31]. This study is an
observational study without randomization, and thus the
results might be influenced by uncontrolled confounders.
In order to optimally limit this source of bias inherent to
all observational study designs, multivariate analysis
including important potential confounders was performed
by using a set of different models. All of them showed
consistent results, suggesting a comfortable degree of
robustness for our findings. The loss to follow-up propor-
tion of this study was 22%, which is to be expected in
this kind of outpatient setting with unrestricted choice of
Table 3 Identification of independent risk factors for incident markers of chronic kidney disease by a multivariate modified Poisson regression
model, accounting for interaction




uPCR 100–500 mg/g at baseline 2.4899 0.02
In PLWHA taking TDF 0.17 1.67 0.81–3.33
In PLWHA not taking TDF 0.02 12.1 1.40–104
Age per year 0.0364 0.07
In PLWHA with:
Serum creatinine < 0.9 mg/dL 0.16 0.96 0.91-1.01
CD4 nadir 500/µL
In PLWHA with:
Serum creatinine < 0.9 mg/dL 0.67 1.01 0.98-1.04
CD4 nadir 200/µL
In PLWHA with:
Serum creatinine > 0.8 mg/dL 0.80 1.01 0.96-1.06
CD4 nadir 500/µL
In PLWHA with:
Serum creatinine > 0.8 mg/dL 0.002 1.05 1.02-1.09
CD4 nadir 200/µL
Serum creatinine > 0.8 mg/dL 1.9659 0.12
In PLWHA aged 50 years 0.49 1.26 0.66–2.39
In PLWHA aged 70 years 0.01 3.02 1.25–7.28
CD4 nadir per cell/µL 0.0059 0.07
In PLWHA aged 50 years 0.14 0.999 0.997–1.001
In PLWHA aged 70 years 0.02 0.996 0.992–0.996
Relevant confounders adjusted for:
Current TDF exposure 2.3083 0.03
Current ATV exposure 0.5502 0.27
Arterial hypertension 0.2196 0.54
Anti-HCV antibody-positive 0.7461 0.30
Significant interaction terms
uPCR 100–500 mg/g 9 TDF 1.9929 0.08
TDF 9 ATV 2.0360 0.09
Age 9 serum creatinine > 0.8 mg/dL 0.0439 0.05
Age 9 CD4 nadir 0.0001 0.03
Age and CD4 count were entered into the model as continuous variables, and therefore calculation of adjusted relative risk (aRR) estimates was per-
formed for exemplary values.
ATV, atazanavir; CD4, CD4-positive T-helper lymphocytes; HCV, hepatitis C virus; PLWHA, people living with HIV/AIDS; TDF, tenofovir disoproxil fuma-
rate; uPCR, urinary protein/creatinine ratio. Statistically significant associations shown in bold.
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provider over a 240-week interval. To confirm that the loss
to follow-up was non-informative, we conducted a com-
parative analysis with the former publication of the initial
study [22]. This comparison demonstrated that there are no
significant deviations with respect to relevant characteris-
tics between the two study populations (data not shown).
We assessed kidney function by blood and urine tests only;
no imaging or histological data were used. Also, only sin-
gle time point data were evaluated for incident markers of
CKD in order to not place additional burden on patients by
exceeding the spectrum of tests at the routine check-ups.
Consequently, the estimated risk for developing CKD could
be both underrated due to missing histology or imaging
data or overrated due to chance observations that would
not have been confirmed. However, both effects would
equally apply to both groups in our cohort so the estimates
for the (adjusted) relative risks are not influenced by this
potential misclassification bias. Finally, this being a real-
life observational study, our findings may better represent
the current situation of PLWHA compared with data from
idealized conditions in randomized studies.
In conclusion, we identified medium-grade proteinuria
in PLWHA as an independent risk factor for developing
markers of CKD, more than doubling the risk. For patients
not using TDF, the risk associated with medium-grade pro-
teinuria is even significantly higher. With age being the
other independent but obviously non-modifiable risk fac-
tor, quantitative urinalysis is a readily available and
important tool for early risk detection and PLWHA should
be checked regularly for proteinuria and signs of CKD. The
recently lowered uPCR cut-off levels triggering further
nephrological work-up, as now recommended by EACS,
support the importance of timely identification, and poten-
tially modification, of CKD risk factors in PLWHA.
Decreasing the uPCR cut-off even further to 100 mg/g may
be considered in order to increase sensitivity.
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